PDF(932 KB)
PDF(932 KB)
PDF(932 KB)
极早发型炎症性肠病的特点与治疗
Features and management of very early onset inflammatory bowel disease
炎症性肠病（IBD）是一种病因不明的慢性非特异性肠道炎症性疾病。该疾病包括3种主要类型：克罗恩病（CD）、溃疡性结肠炎（UC）和未分型IBD（IBD-U）。IBD在成人中发病率高，但近年来，IBD在儿童中发病率越来越高。极早发型IBD（VEO-IBD）是儿童IBD的一部分，有其独特的表型和遗传学特征，通常病情严重，并且对常规IBD治疗效果差。该文对VEO-IBD的临床特点、发病机制和治疗进行了综述。
Inflammatory bowel disease (IBD) is a chronic nonspecific intestinal inflammatory disease of unknown etiology. This disease includes three main types:Crohn's disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U). IBD is frequently presented in adults, but in recent years, there is a rising incidence in pediatric populations. Very early onset IBD (VEO-IBD) is a fraction of pediatric IBD, but they have exclusive phenotypic and genetic characteristics such that they are accompanied by severe disease course and resistance to conventional therapy. The purpose of this review is to provide a contemporary overview of the clinical features, pathogenesis, and management of VEO-IBD.
Very early onset inflammatory bowel disease / Clinical feature / Management / Child
[1] 罗优优(译者). 欧洲儿科胃肠病学、肝病学和营养协会儿童及青少年炎症性肠病诊断的改良波尔图标准(2014年版)[J]. 中华儿科杂志, 2016, 54(10):728-732.
[2] Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease:a systematic review of international trends[J]. Inflamm Bowel Dis, 2011, 17(1):423-439.
[3] Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland[J]. Inflamm Bowel Dis, 2012, 18(6):999-1005.
[4] Kelsen JR, Conrad MA, Simon L, et al. Using functional assays in patient-derived enteroids to understand genotype-phenotype interactions in very early onset inflammatory bowel disease (VEO-IBD)[J]. Gastroenterology, 2017, 152(5):S351.
[5] Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease:controversies, consensus, and implications[J]. Gut, 2006, 55(6):749-753.
[6] Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease:the Paris classification[J]. Inflamm Bowel Dis, 2011, 17(6):1314-1321.
[7] de Bie CI, Buderus S, Sandhu BK, et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe:results of a 5-year audit of the EUROKIDS registry[J]. J Pediatr Gastroenterol Nutr, 2012, 54(3):374-380.
[8] Prenzel F, Uhlig HH. Frequency of indeterminate colitis in children and adults with IBD-a meta analysis[J]. J Crohns Colitis, 2009, 3(4):277-281.
[9] Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2014, 58(6):795-806.
[10] Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis:joint ECCO and ESPGHAN evidence-based consensus guidelines[J]. J Pediatr Gastroenterol Nutr, 2012, 55(3):340-361.
[11] Fiskerstrand T, Arshad N, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation[J]. N Engl J Med, 2012, 366(17):1586-1595.
[12] Blaydon DC, Biancheri P, Di WL, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion[J]. New Engl J Med, 2011, 365(16):1502-1508.
[13] Catucci M, Castiello MC, Pala F, et al. Autoimmunity in WiskottAldrich syndrome:an unsolved enigma[J]. Front Immunol, 2012, 3(3):209.
[14] Chen R, Giliani S, Lanzi G, et al. Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias[J]. J Allergy Clin Immunol, 2013, 132(3):656-664. e17.
[15] Samuels ME, Majewski J, Alirezaie N, et al. Exome sequencing identifies mutations in the gene TTC7A in French-Canadian cases with hereditary multiple intestinal atresia[J]. J Med Genet, 2013, 50(5):324-329.
[16] Muise AM, Xu W, Guo CH, et al. NADPH oxidase complex and IBD candidate gene studies:identification of a rare variant in NCF2 that results in reduced binding to RAC2[J]. Gut, 2012, 61(7):1028-1035.
[17] Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib:results of the European Study on Glycogen Storage Disease type I[J]. J Pediatr, 2000, 137(2):187-191.
[18] Bégin P, Patey N, Mueller P, et al. Inflammatory bowel disease and T cell lymphopenia in G6PC3 deficiency.[J]. J Clin Immunol, 2013, 33(3):520-525.
[19] Glocker E, Grimbacher B. Inflammatory bowel disease:is it a primary immunodeficiency?[J]. Cell Mol Life Sci, 2012, 69(1):41-48.
[20] Agarwal S, Smereka P, Harpaz N, et al. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease[J]. Inflamm Bowel Dis, 2011, 17(1):251-259.
[21] Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades[J]. Blood, 2012, 119(7):1650-1657.
[22] Alangari A, Alsultan A, Adly N, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency[J]. J Allergy Clin Immun, 2012, 130(2):481-488. e2.
[23] Lopez-Herrera G, Tampella G, Pan-Hammarström Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity[J]. Am J Hum Genet, 2012, 90(6):986-1001.
[24] Burns SO, Zenner HL, Plagnol V, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia[J]. J Allergy Clin Immun, 2012, 130(6):1428-1432.
[25] Yang X, Kanegane H, Nishida N, et al. Clinical and genetic characteristics of XIAP deficiency in Japan[J]. J Clin Immunol, 2012, 32(3):411-420.
[26] Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis:successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease[J]. Genet Med, 2011, 13(3):255-262.
[27] Speckmann C, EhI S. XIAP deficiency is a mendelian cause of late-onset IBD[J]. Gut, 2014, 63(6):1031-1032.
[28] Notarangelo LD. Functional T cell immunodeficiencies (with T cells present)[J]. Annu Rev Immunol, 2013, 31:195-225.
[29] Avitzur Y, Guo C, Mastropaolo LA, et al. Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease[J]. Gastroenterology, 2014, 146(4):1028-1039.
[30] 许永彬, 陈玉冰, 曾萍, 等. 白细胞介素10受体突变引起新生儿期炎症性肠病的发病机制及基因诊断[J]. 中华儿科杂志, 2015, 53(5):348-354.
[31] 彭凯玥, 钱晓文, 吴冰冰, 等. 脐血干细胞移植治疗白介素10受体A基因突变导致的极早发型炎症性肠病1例病例报告并文献复习[J]. 中国循证儿科杂志, 2016, 11(3):171-176.
[32] Aloi M, Lionetti P, Barabino A, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2014, 20(4):597-605.
[33] 刘黎黎, 姜毅, 侯新琳, 等. 4月龄以内起病的炎症性肠病7例临床特点及基因诊断病例系列报告[J]. 中国循证儿科杂志, 2016, 11(4):285-289.
[34] 李峰, 晋红中. 119例英夫利西单抗不良反应的文献分析[J]. 中国药物警戒, 2016, 13(4):229-232.
[35] Ford AC, Bernstein CN, Khan K J, et al. Glucocorticosteroid therapy in inflammatory bowel disease:systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4):590-599.
[36] Beser OF, Conde CD, Serwas NK, et al. Clinical features of interleukin 10 receptor gene mutations in children with very early-onset inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2015, 60(3):332-338.
[37] Working Group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition; Konno M, Kobayashi A, Tomomasa T, et al. Guidelines for the treatment of Crohn's disease in children[J]. Pediatr Int, 2006, 48(3):349-352.
[38] 王琳, 黄瑛. 沙利度胺在儿童炎症性肠病中的作用[J]. 临床儿科杂志, 2014, 32(10):998-1000.
[39] 周怡, 刘红春. 益生菌在炎症性肠病中的治疗进展[J]. 胃肠病学和肝病学杂志, 2015, 24(1):1-3.
[40] Walters TD, Griffths AM. Growth Impairment in Pediatric Inflammatory Bowel disease[M]. New York:Springer, 2008:109-126.
[41] Leach ST, Mitchell HM, Eng WR, et al. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease[J]. Aliment Pharmacol Ther, 2008, 28(6):724-733.
[42] Altomare R, Damiano G, Abruzzo A, et al. Enteral nutrition support to treat malnutrition in inflammatory bowel disease[J]. Nutrients, 2015, 7(4):2125-2133.
[43] Srivastava AS, Feng Z, Mishra R, et al. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice[J]. Biochem Biophys Res Commun, 2007, 361(4):953-959.
[44] Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease[J]. Gut, 2008, 57(2):211-217.
[45] Yanagi T, Mizuochi T, Takaki Y, et al. Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease:a case report[J]. BMC Gastroenterol, 2016, 16:10.
[46] Shaker A, Rubin DC. Stem cells:One step closer to gut repair[J]. Nature, 2012, 485(7397):181-182.
[47] Irhimeh MR, Cooney J. Management of inflammatory bowel disease using stem cell therapy[J]. Curr Stem Cell Res Ther, 2016, 11(1):72-77.
